Welcome to our dedicated page for JOINT SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Joint Corp. filings document the regulatory record for a public chiropractic-care franchisor and clinic operator. Its 8-K reports cover operating and financial results, earnings presentations, material agreements, and capital-structure matters tied to credit facilities, covenants, restricted payments, and share repurchase capacity.
Proxy and governance filings describe director elections, board nomination matters, executive compensation, equity awards, shareholder voting items, and common-stock ownership disclosures. The company’s formal filings also record agreements related to corporate governance and the financing structure that supports its franchise-focused clinic network.
Form 144 notice for The Joint Corp. (JYNT) reports a proposed sale of 12,000 shares of common stock via Raymond James on 08/29/2025 with an aggregate market value of $127,920. The filing shows the 12,000 shares were acquired through RSU vesting on multiple dates between 08/07/2021 and 05/25/2024, and that the planned sale equals the total of those vested RSUs. The issuer's outstanding shares are listed as 15,340,000, and the filing also discloses a prior sale by the same person of 20,000 common shares on 08/22/2025 for gross proceeds of $215,000. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
The company disclosed the departure of its Chief Financial Officer, Mr. Singleton, whose role ceased effective June 9, 2025. The company and Mr. Singleton entered a separation agreement dated August 22, 2025 that includes a general release and a revocation period. If not revoked, the agreement provides Separation Benefits: a cash payment equal to six months of base salary, a cash payment for accumulated time off of $36,193.99, an additional cash payment of $15,000, reimbursement for accrued expenses per company policy, and payment of up to six months of COBRA health-insurance cost if elected. Outstanding equity awards will be governed by existing award agreements and plans and will not receive accelerated vesting under the Separation Agreement.
The filer submitted a Form 144 to notify a proposed sale of 20,000 common shares of The Joint Corp. (JYNT) through Raymond James & Associates on NASDAQ, with an aggregate market value of $215,000 and approximately 15,340,000 shares outstanding. The shares were acquired by the same person through two stock option exercises: 10,289 shares on 08/22/2025 and 9,711 shares on 08/25/2025, each paid in cash on the exercise dates. The filer reports no securities sold in the past three months. The form includes the routine certification that the seller is not aware of undisclosed material adverse information. Certain filer identification fields in the provided content are blank.
The reporting person, Christopher M. Grandpre, a director of The Joint Corp. (JYNT), purchased 10,000 shares of the issuer's common stock on 08/20/2025 at a weighted-average price of $10.4082 per share. After the reported acquisition, the reporting person beneficially owns 39,383 shares in total. The filing was signed by an attorney-in-fact on 08/22/2025. The footnote clarifies the reported price is a weighted average covering multiple purchases at prices ranging from $10.30 to $10.57, and the reporting person will provide breakdowns on request.
Charles E. Jobson filed an amended Schedule 13G reporting beneficial ownership of 1,075,994 shares of JOINT Corp common stock (CUSIP 47973J102), representing 7.01% of the class. The filing states Mr. Jobson has sole voting and sole dispositive power over all reported shares, and no shared voting or dispositive arrangements are reported. The document lists JOINT Corp's principal executive office in Scottsdale, Arizona, and Mr. Jobson's residence in Wellesley, Massachusetts. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and certification language attests to the accuracy of the statement.
Christopher M. Grandpre, a director of The Joint Corp. (JYNT), reported two open-market purchases of the issuer's common stock in mid-August 2025. The filing shows a purchase of 14,388 shares on 08/15/2025 at a weighted average price of $10.8793 and a subsequent purchase of 10,000 shares on 08/18/2025 at a weighted average price of $10.6978. Following these transactions he beneficially owned 29,383 shares as a direct owner. The filing was submitted under a Form 4 and signed by an attorney-in-fact on 08/19/2025. No derivative transactions, dispositions, or additional contextual details about the purpose of the purchases are provided in this document.
Schedule 13G filing overview – The Joint Corp. (JYNT)
On 10 July 2025, Skylands Capital, LLC, a Wisconsin-based investment adviser, submitted a Schedule 13G reporting its beneficial ownership in The Joint Corp. common stock. The filing relates to an event dated 30 June 2025.
- Shares owned: 779,295
- % of outstanding class: 5.1%
- Voting power: Sole power to vote and dispose of all reported shares; no shared power
- Filing basis: Rule 13d-1(b) – passive investment by an investment adviser (IA)
- Intent statement: Securities acquired and held in the ordinary course, not for the purpose of influencing control
The disclosure means Skylands has crossed the 5 % reporting threshold, giving investors fresh insight into institutional ownership dynamics at The Joint Corp. No other entities or group relationships are identified, and there are no indications of activist intent.